Tetrahydrocannabivarin may be beneficial in typ 2 diabetes according to a clinical study

Tetrahydrocannabivarin may be beneficial in typ 2 diabetes according to a clinical study

Por: IACM Medicinal

The plant cannabinoid THCV (tetrahydrocannabivarin) decreases glucose levels and may have further beneficial effects in patients with type 2 diabetes. This is the result of research by scientists from Nottingham, London and Oxford in the UK, published in Diabetes Care. They included 62 patients with noninsulin-treated type 2 diabetes in a placebo-controlled study with CBD (100 mg twice daily), THCV (5 mg twice daily), a combination of CBD and THCV (5 mg of both cannabinoids twice daily), and a 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily).

Compared with placebo, THCV significantly decreased fasting plasma glucose and improved the function of cells in the pancreas, which are responsible for insulin production (HOMA2 beta-cell function). It also improved the values for adiponectin and apolipoprotein A. There was no difference between CBD and placebo. None of the combination treatments had a significant impact on end points. CBD and THCV were well tolerated. Authors concluded that “THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.”

Check the study here.

Source: http://www.cannabis-med.org/english/bulletin/iacm.php

Kannabia Seed Company vende a sus clientes un producto de colección, un souvenir. No podemos y no daremos consejos de cultivo ya que nuestro producto no está diseñado para este propósito.

Kannabia no se responsabiliza del uso indebido que terceros hagan de la información publicada. El cultivo de cannabis para consumo personal es una actividad sujeta a restricciones legales que varían de estado a estado. Recomendamos consultar la legislación vigente en su país de residencia para evitar la participación en cualquier actividad ilegal.

Comparte: